Penumbra, Inc. (NYSE:PEN) – Research analysts at Truist Securiti issued their Q3 2021 earnings estimates for Penumbra in a note issued to investors on Wednesday, September 15th. Truist Securiti analyst D. Rescott forecasts that the company will post earnings of $0.19 per share for the quarter. Truist Securiti also issued estimates for Penumbra’s Q4 2021 earnings at $0.25 EPS, FY2021 earnings at $0.91 EPS, Q1 2022 earnings at $0.28 EPS, Q2 2022 earnings at $0.39 EPS, Q3 2022 earnings at $0.41 EPS, Q4 2022 earnings at $0.49 EPS, FY2022 earnings at $1.57 EPS and FY2023 earnings at $2.23 EPS.
Penumbra (NYSE:PEN) last announced its earnings results on Monday, August 9th. The company reported $0.21 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.02. Penumbra had a return on equity of 5.52% and a net margin of 2.37%. The firm had revenue of $184.26 million during the quarter, compared to analysts’ expectations of $170.77 million. During the same quarter in the previous year, the business earned ($0.30) EPS. The company’s quarterly revenue was up 75.3% on a year-over-year basis.
Shares of PEN stock opened at $277.68 on Monday. The stock has a market cap of $10.16 billion, a PE ratio of 645.77, a price-to-earnings-growth ratio of 13.67 and a beta of 0.28. Penumbra has a 52-week low of $163.49 and a 52-week high of $320.00. The company has a quick ratio of 3.68, a current ratio of 6.04 and a debt-to-equity ratio of 0.04. The business has a 50-day simple moving average of $267.24 and a 200-day simple moving average of $270.58.
In other Penumbra news, Director Thomas Wilder sold 161 shares of the business’s stock in a transaction on Monday, July 12th. The shares were sold at an average price of $275.09, for a total value of $44,289.49. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Adam Elsesser sold 14,500 shares of the company’s stock in a transaction dated Wednesday, August 11th. The shares were sold at an average price of $251.24, for a total transaction of $3,642,980.00. Following the completion of the sale, the chief executive officer now owns 14,500 shares in the company, valued at approximately $3,642,980. The disclosure for this sale can be found here. Insiders have sold a total of 45,023 shares of company stock valued at $11,986,518 over the last three months. Corporate insiders own 7.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in shares of Penumbra in the 1st quarter valued at approximately $9,254,000. Aegon Asset Management UK PLC lifted its position in shares of Penumbra by 14.9% in the 2nd quarter. Aegon Asset Management UK PLC now owns 29,335 shares of the company’s stock valued at $8,047,000 after acquiring an additional 3,793 shares in the last quarter. Financial Counselors Inc. lifted its position in shares of Penumbra by 13.3% in the 2nd quarter. Financial Counselors Inc. now owns 850 shares of the company’s stock valued at $233,000 after acquiring an additional 100 shares in the last quarter. South Dakota Investment Council lifted its position in shares of Penumbra by 6.2% in the 1st quarter. South Dakota Investment Council now owns 5,310 shares of the company’s stock valued at $1,437,000 after acquiring an additional 310 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Penumbra by 65.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $1,215,000 after acquiring an additional 1,783 shares in the last quarter. Institutional investors and hedge funds own 80.61% of the company’s stock.
Penumbra Company Profile
Penumbra, Inc engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists.
Read More: Analyst Ratings Trading
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.